U.S. markets closed
  • S&P Futures

    -4.00 (-0.11%)
  • Dow Futures

    -16.00 (-0.05%)
  • Nasdaq Futures

    -31.00 (-0.25%)
  • Russell 2000 Futures

    -6.20 (-0.29%)
  • Crude Oil

    +0.65 (+1.02%)
  • Gold

    -11.60 (-0.68%)
  • Silver

    -0.21 (-0.83%)

    -0.0020 (-0.17%)
  • 10-Yr Bond

    +0.0800 (+5.44%)
  • Vix

    +1.90 (+7.12%)

    -0.0009 (-0.06%)

    +0.1050 (+0.10%)

    -2,598.88 (-5.23%)
  • CMC Crypto 200

    -44.87 (-4.55%)
  • FTSE 100

    -24.59 (-0.37%)
  • Nikkei 225

    -128.70 (-0.44%)

UPDATE 2-Pfizer to ship 13 mln COVID-19 vaccine doses per week to U.S. by mid-March, says executive

  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.
Carl O'Donnell
·2 min read
  • Oops!
    Something went wrong.
    Please try again later.
  • Oops!
    Something went wrong.
    Please try again later.

(Adds commentary from AstraZeneca)

By Carl O'Donnell

Feb 22 (Reuters) - Pfizer Inc expects to delivermore than 13 million doses of its COVID-19 vaccine per week tothe United States by the middle of March, more than doubling itsshipments from early February, a top Pfizer executive said inprepared testimony ahead of a Tuesday congressional hearing.

Pfizer is on track to deliver 120 million doses of itstwo-dose regimen by the end of March, said John Young, Pfizer'schief business officer.

Pfizer is also prepared to provide a total of 300 millionshots to the United States by the end of July and has raisedglobal production expectations for 2021 to at least 2 billiondoses, he said.

In his own prepared remarks, Moderna Inc PresidentStephen Hoge said the drugmaker plans to deliver 100 milliondoses of its two-dose shot by the end of March, and 300 millionby the end of July.

Johnson & Johnson believes it will be able to shipat least 20 million doses of its single-dose shot to the UnitedStates by the end of March after receiving U.S. regulatoryauthorization and 100 million doses by mid-year 2021, said VicePresident of Medical Affairs Richard Nettles.

The comments were prepared ahead of a U.S. congressionalhearing on vaccine availability to be held by the HouseCommittee on Energy and Commerce on Tuesday as the United Statescrossed the staggering milestone of 500,000 COVID-19 deaths.

The remarks put the United States on track to receive 240million doses by the end of March, enough to inoculate 130million Americans, and 700 million doses by mid-year.

AstraZeneca Plc, which is running a U.S. trial for itscoronavirus vaccine, believes it can quickly adapt its shot tonew variants of the virus in its laboratory, said Ruud Dobber,company president, North America.

A highly contagious COVID-19 variant has become prevalent inSouth Africa and has turned up in several U.S. states.(Reporting by Carl O'Donnell in New YorkEditing by Rosalba O'Brien, Matthew Lewis and Ana Nicolaci daCosta)